Gilead Sciences up 10% Despite Lower Than Expected Q4 Profit

Gilead Sciences GILD is trading higher pre-market following its Q4 earnings announcement. The company reported EPS of $0.97 vs $1.05 estimate and revenues $2.20 billion vs $2.18 billion estimate. Gilead Sciences is a biopharmaceutical company focusing on the development and commercialization of human therapeutics for life threatening diseases. The stock is up 20% year-to-date trading at its highs since early 2010. The shares of Gilead are currently trading at $54.53, up $5.22 or 10.59%.